A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

被引：0
|
作者：
Takeo Fujii
Hiroko Masuda
Yee Chung Cheng
Fei Yang
Aysegul A. Sahin
Yasuto Naoi
Yuki Matsunaga
Akshara Raghavendra
Arup Kumar Sinha
Jose Rodrigo Espinosa Fernandez
Anjali James
Keisuke Yamagishi
Tomoko Matsushima
Robert Schuetz
Debu Tripathy
Sachiyo Tada
Rubie S. Jackson
Shinzaburo Noguchi
Seigo Nakamura
Jared D. Acoba
Naoto T. Ueno
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Breast Medical Oncology
[2] The University of Texas MD Anderson Cancer Center,Section of Translational Breast Cancer Research, Department of Breast Medical Oncology, Unit 1354
[3] University of Hawai’i,John A. Burns School of Medicine
[4] University of Hawai’i Cancer Center,Department of Breast Surgical Oncology
[5] Showa University,Division of Hematology and Oncology
[6] Medical College of Wisconsin,Department of Translational Molecular Pathology
[7] The University of Texas MD Anderson Cancer Center,Department of Pathology
[8] The University of Texas MD Anderson Cancer Center,Department of Breast and Endocrine Surgery
[9] Osaka University Graduate School of Medicine,Anne Arundel Medical Center
[10] Sysmex Corporation,undefined
[11] Rebecca Fortney Breast Center,undefined
[12] Hyogo Prefectural Nishinomiya Hospital,undefined
来源：
Breast Cancer Research and Treatment | 2021年 / 189卷
关键词：
Breast cancer; 21-gene signature assay; 95-gene signature assay; Estrogen receptor-positive; Recurrence Score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：455 / 461
页数：6
相关论文
共 50 条
  • [41] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Weiser, Roi
    Haque, Waqar
    Polychronopoulou, Efstathia
    Hatch, Sandra S.
    Kuo, Yong-fang
    Gradishar, William J.
    Klimberg, V. Suzanne
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) : 667 - 676
  • [42] The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis
    Roi Weiser
    Waqar Haque
    Efstathia Polychronopoulou
    Sandra S. Hatch
    Yong-fang Kuo
    William J. Gradishar
    V. Suzanne Klimberg
    Breast Cancer Research and Treatment, 2021, 185 : 667 - 676
  • [43] Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
    Han, Yunan
    Miao, Zhi-Feng
    Lian, Min
    Peterson, Lindsay L.
    Colditz, Graham A.
    Liu, Ying
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 184 (03) : 915 - 925
  • [44] Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer
    Yunan Han
    Zhi-Feng Miao
    Min Lian
    Lindsay L. Peterson
    Graham A. Colditz
    Ying Liu
    Breast Cancer Research and Treatment, 2020, 184 : 915 - 925
  • [45] Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
    Chae, Eun Young
    Moon, Woo Kyung
    Kim, Hak Hee
    Kim, Won Hwa
    Cha, Joo Hee
    Shin, Hee Jung
    Choi, Woo Jung
    Han, Wonshik
    Noh, Dong-Young
    Lee, Sae Byul
    Ahn, Sei Hyun
    PLOS ONE, 2016, 11 (06):
  • [46] Validation of the prognosis of patients with ER-positive, HER2-negative and node-negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi-institutional registry study
    Naoi, Yasuto
    Tsunashima, Ryo
    Shimazu, Kenzo
    Oikawa, Masahiro
    Imanishi, Seiichi
    Koyama, Hiroshi
    Kamada, Yoshihiko
    Ishihara, Kazuhiro
    Suzuki, Masahiko
    Osako, Tomo
    Kinoshita, Takayuki
    Suto, Akihiko
    Nakamura, Seigo
    Tsuda, Hitoshi
    Noguchi, Shinzaburo
    ONCOLOGY LETTERS, 2023, 25 (05)
  • [47] Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
    Dowsett, Mitch
    Cuzick, Jack
    Wale, Christopher
    Forbes, John
    Mallon, Elizabeth A.
    Salter, Janine
    Quinn, Emma
    Dunbier, Anita
    Baum, Michael
    Buzdar, Aman
    Howell, Anthony
    Bugarini, Roberto
    Baehner, Frederick L.
    Shak, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : 1829 - 1834
  • [48] Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
    Vera-Badillo, Francisco E.
    Chang, Martin C.
    Kuruzar, Gordana
    Ocana, Alberto
    Templeton, Arnoud J.
    Seruga, Bostjan
    Goldstein, Robyn
    Bedard, Philippe L.
    Tannock, Ian F.
    Amir, Eitan
    JOURNAL OF CLINICAL PATHOLOGY, 2015, 68 (10) : 839 - 843
  • [49] Metabolic syndrome and recurrence within the 21-gene recurrence score assay risk categories in lymph node negative breast cancer
    Lakhani, A.
    Guo, R.
    Duan, X.
    Ersahin, C.
    Gaynor, E. R.
    Godellas, C.
    Kay, C.
    Lo, S. S.
    Mai, H.
    Perez, C.
    Albain, K.
    Robinson, P.
    CANCER RESEARCH, 2012, 72
  • [50] Using the 21-gene recurrence score and the recently developed Recurrence Score-Clinical-Pathologic to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.
    Crager, M.
    Tang, G.
    Shak, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345